Amundi Has $18.63 Million Holdings in Sanofi $SNY

Amundi decreased its position in Sanofi (NASDAQ:SNY - Free Report) by 45.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 341,045 shares of the company's stock after selling 289,018 shares during the quarter. Amundi's holdings in Sanofi were worth $18,628,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Accent Capital Management LLC acquired a new stake in Sanofi in the first quarter valued at approximately $29,000. Eastern Bank raised its holdings in Sanofi by 121.0% in the first quarter. Eastern Bank now owns 548 shares of the company's stock valued at $30,000 after acquiring an additional 300 shares in the last quarter. Golden State Wealth Management LLC raised its holdings in Sanofi by 619.3% in the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock valued at $35,000 after acquiring an additional 545 shares in the last quarter. Brentview Investment Management LLC acquired a new stake in Sanofi in the first quarter valued at approximately $42,000. Finally, UMB Bank n.a. increased its stake in Sanofi by 30.7% in the first quarter. UMB Bank n.a. now owns 1,124 shares of the company's stock valued at $62,000 after purchasing an additional 264 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.

Sanofi Price Performance

SNY stock traded down $0.62 during trading hours on Friday, hitting $47.03. 2,728,115 shares of the stock traded hands, compared to its average volume of 2,650,921. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19. Sanofi has a one year low of $44.73 and a one year high of $60.12. The company has a market cap of $115.48 billion, a P/E ratio of 11.31, a P/E/G ratio of 1.13 and a beta of 0.51. The stock has a 50-day simple moving average of $48.64 and a 200 day simple moving average of $51.13.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The business had revenue of $11.34 billion for the quarter, compared to analyst estimates of $9.91 billion. During the same quarter in the previous year, the business posted $1.73 earnings per share. The company's revenue was down 7.0% compared to the same quarter last year. Equities analysts forecast that Sanofi will post 4.36 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Wall Street Zen upgraded shares of Sanofi from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Morgan Stanley raised Sanofi from an "equal weight" rating to an "overweight" rating and lifted their price target for the stock from $56.00 to $58.00 in a research note on Monday, September 8th. Barclays restated an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "hold" rating to a "buy" rating in a report on Tuesday, September 2nd. Finally, JPMorgan Chase & Co. upgraded Sanofi from a "neutral" rating to an "overweight" rating in a research note on Friday, August 8th. Three investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $62.67.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.